Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The world’s largest genetic study into depression has uncovered life-changing discoveries that will revolutionise treatments ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...